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Abstract
Background: Anti-Mu ¨llerian hormone (AMH) is a product of growing ovarian follicles. The concentration of AMH in blood
may also reflect the non-growing follicle (NGF) population, i.e. the ovarian reserve, and be of value in predicting
reproductive lifespan. A full description of AMH production up to the menopause has not been previously reported.
Methodology/Principal Findings: By searching the published literature for AMH concentrations in healthy pre-menopausal
females, and using our own data (combined n~3,260) we have generated and robustly validated the first model of AMH
concentration from conception to menopause. This model shows that 34% of the variation in AMH is due to age alone. We
have shown that AMH peaks at age 24.5 years, followed by a decline to the menopause. We have also shown that there is a
neonatal peak and a potential pre-pubertal peak. Our model allows us to generate normative data at all ages.
Conclusions/Significance: These data highlight key inflection points in ovarian follicle dynamics. This first validated model
of circulating AMH in healthy females describes a transition period in early adulthood, after which AMH reflects the
progressive loss of the NGF pool. The existence of a neonatal increase in gonadal activity is confirmed for females. An
improved understanding of the relationship between circulating AMH and age will lead to more accurate assessment of
ovarian reserve for the individual woman.
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Introduction
The human ovary establishes its complete complement of
primordial follicles during fetal life, with recruitment and thereby
depletion of this dormant primordial follicle pool required for
normal fertility but ultimately leading to reproductive senescence
[1]. Primordial follicles are recruited continuously from before
birth to join the early growing cohort (initial recruitment). After
puberty, at every new cycle a limited number of follicles are
recruited from this cohort of small growing follicles (cyclic
recruitment), followed by a final selection for dominance and
ovulation of a single follicle [2,3]. Thus, at any specific time, the
majority of primordial follicles are held in a dormant state, and
when eventually recruited most will not reach the preovulatory
stage but are destined to be removed through atresia at earlier
stages of follicular development. Currently, clinical assessment is
unable to assess the number of primordial follicles, or their rate of
loss/activation. Knowledge of these aspects of ovarian function
would be of value in a range of contexts, both clinical and social/
personal, as well as being of great value in promoting our
understanding of how reproductive lifespan is regulated.
Anti-Mu ¨llerianhormone(AMH),isnowrecognizedasaprincipal
regulator of early follicular recruitment from the primordial pool
[4,5], with AMH null mice demonstrating accelerated depletion of
primordial follicle number and an almost three-fold increase in
smallergrowingfollicles[6].Furthermore this increase in number of
growing follicles occurs despite lower serum follicle stimulating
hormone (FSH) concentrations [7], suggesting that in the absence of
AMH, follicles are more sensitive to FSH and progress through the
early stages of follicular development. AMH is produced by small
growing but not primordial follicles [8–10], although limited data
suggest that serum AMH concentrations also correlate with
primordial follicle number in humans [11] as in rodents [12]. The
prepubertal endocrine environment is markedly different from the
adult with low and non-cyclical gonadotropins: the relevance of this
to AMH secretion is incompletely understood although follicle
growth through the preantral stages and occasionally to early antral
stages (i.e. across the full range of stages that secrete AMH) is
observed in childhood [13]. A recent study has reported an increase
in initial primordial follicular recruitment rates up to the age of
puberty, and then a progressive decline to the menopause [14]. This
suggests that AMH concentrations at any given age in both
childhood and adulthood may mirror primordial follicular recruit-
ment rates, rather than simply primordial follicle number.
Consequently across the female lifespan, circulating AMH will
potentially exhibit an initial increase followed by a non-linear
decline as is well established for the primordial follicle pool [14–18].
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shown to decline with age [19,20]. AMH concentrations are
relatively stable across the menstrual cycle [21,22] and also between
cycles in the same woman [23]. Measurement of AMH is
increasingly used in the prediction of ovarian response to
superovulation [24]. Although large AMH cohort studies describing
falling AMH concentrations in adult women (mostly from
populations attending infertility clinics) have recently been pub-
lished [25–28], the data for AMH concentrations in children have
until recently been considerably more limited [29,30]. To date no
single study has examined AMH across the lifespan in healthy
females. The aim of the current study is to produce a model of
serum AMH in healthy females from conception to the menopause.
Results
The validated model
Data from published studies and our own (Table 1) were used to
derive the model (Figure 1). This included 3,260 data points across
the age range from 20.3 (cord blood from preterm infants) to 54.3
years (Table 2). After 10-fold stratified cross-validation, the model
with the highest coefficient of determination (r2) was a degree 20
polynomial of the form
log10(AMHz1)~c0zc1agezc2age2z...zc20age20
with coefficients cj given in Table 3.
This model has an r2 of 0.34, indicating that roughly one third
of variation in AMH concentrations is due to age alone, with the
remaining two thirds of the variation being due to other factors.
Serum AMH peaks at 24.5 years on average, with concentrations
decreasing shortly after birth, and again between eight and twelve
years of age.
Validation
For each of the 10 folds of the validation process, the highest
ranked of 215 models was a polynomial similar to the model
reported above: in every case the returned coefficients, r2 and
peaks were similar (Table 4). Moreover, the average training
error was within 1% of the average cross-validation estimate of
the prediction error across 10 folds (Table 4). We therefore
consider that the model derived for all 3,260 datapoints
generalises well to unseen data, and hence report this as a
validated model for serum AMH concentrations in the normal
female population (Figure 2).
Table 1. Serum AMH data summary.
Ref. 1
st Author Data Assay n Average age Age range Det. lim. Intra CV Inter CV
[35] Soto Graph IBC 58 30.3 (mean) +8:7 SD 0.10 5.3 8.7
[38] Guibourdenche Graph IBC 192 NS 20.3–1.0 0.30 5.3 8.7
[39] Hudecova Graph IBC 64 46.3 (mean) +6:4 SD 0.70 12.3 12.3
[40] Mulders Graph IBC 82 29.9 19.6–35.6 NS 5.0 8.0
[41] Pastor Graph IBC 42 NS 18.0–50.0 0.10 5.3 7.8
[42] Piltonen Graph IBC 44 31.6 (mean) 21.0–44.0 NS 5.1 6.6
[20] van Rooij Graph IBC 162 NS 25.0–46.0 0.05 5.0 8.0
[43] Laven Graph IBC 41 NS 20.0–36.0 0.05 5.0 8.0
[19] de Vet Graph IBC 82 29.0 +4:0 SD 0.05 5.0 8.0
[44] Knauf Graph IBC 83 34.2 (mean) +3:4 SD 0.03 11.0 11.0
[45] Lee Graph IBC 225 NS 0.0–51.0 0.50 9.0 15.0
[36] La Marca Graph IBC 24 44.0 (mean) +2:8 SD 0.24 5.0 8.0
[29] Hagen Graph IBC 891 NS 0.0–68.0 0.03 7.8 11.6
[46] van Beek Graph DSL 82 29.0 20.0–35.0 NS 5.0 15.0
[47] Sanders Graph DSL 43 24.1 (mean) 0.1–51.0 0.01 NS 11.4
[34] van Disseldorp Graph DSL 144 37.9 (mean) 25.0–46.0 0.03 11.0 11.0
[48] Tehrani Graph DSL 267 27.1 16.0–44.0 0.01 5.2 9.1
[49] Dorgan Graph DSL 204 44.7 (mean) 33.3–54.7 0.06 8.0 8.0
[30] Ahmed Raw DSL 128 8.5 0.5–16.5 0.50 8.0 8.0
[25] Nelson Raw DSL 441 36.1 21.9–47.8 0.03 3.4 8.6
Total IBC 1,990 15.8 20.3–68.0
Total DSL 1,309 35.4 0.2–54.7
Total n 3,299 34.0 20.3–68.0
Censored total n 3,260 28.3 20.3–54.3
The references relate to the bibliography section of this paper. Age information is given as median and range, or as mean and standard devation (SD), depending on
which form was reported in the referenced study. Detection limits are given in ng/ml. Intra- and inter-assay coefficients of variation (CV) are percentages. NS denotes
not stated. For longitudinal studies – [19,29,40,48] – we report the average age of participants at first measurement. The censored total excludes any values greater than
54.3 years (i.e. one standard deviation above the average age at menopause).
doi:10.1371/journal.pone.0022024.t001
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We have generated the first validated model of serum AMH in
the healthy human population from conception to menopausal
ages. Our model shows that serum AMH concentrations peak at
age 24.5 years for the average case, and suggests that two thirds of
the variation in AMH concentrations for healthy females is due to
factors other than age.
We have shown that serum AMH falls shortly after birth, with
concentrations only increasing again after about two years of age.
This feature is in line with evidence of a mini-puberty seen in
neonatal girls [31,32], although more clearly characterized in boys
[33], and with a recent longitudinal study of AMH in female
neonatal blood [29] (the data from which were included in our
study). Our model also shows that serum AMH concentration falls
between the ages of eight and twelve, before rising to a peak in the
mid-twenties. This fall may be an artefact of our model derivation
process rather than a true reproductive biological event. As the fall
coincides with the initial increases in gonadotropin concentrations
of early puberty, it is possible that it reflects changes in the
proportions of follicles at different stages of growth with increasing
numbers progressing to antral stages rather than becoming atretic
early on [3]. AMH is produced by early growing follicles at all
stages up to the early antral stage [8] but it is unknown which
follicle class contributes most to circulating concentrations. The
rising granulosa cell mass (and thus AMH production per follicle)
will be balanced by progressively declining numbers of follicles at
each stage of growth [2,3].
Our incomplete understanding of how early follicle recruitment
and growth are regulated means that any such interpretation is
speculative but our results both suggest this avenue of future
research, and give useful indications of effect sizes and ages for the
design of such investigations.
The increase in AMH during the postnatal period, supported by
a recent longitudinal analysis in the first 3 months of life [29], is
likely to be analogous to the well established transient rise in
testosterone and inhibin B in boys at that time [33]. This is likely
to reflect the relatively high gonadotrophin concentrations that are
present which will support more advanced follicle development
than occurs in the remainder of the prepubertal period. Consistent
with this, the ovary shows follicle growth to the early antral stage
from birth [13]. The continuing rise in AMH through childhood is
striking, and parallels rising follicle growth initiation from the very
large pool at these ages [14]. The rising AMH production would
therefore act to limit follicle growth activation [5,6], thus a point of
inflection when follicle recruitment starts to slow, and which is
followed by a decline in AMH concentrations is predictable: our
data demonstrate the age at which this occurs.
Our observed increase in AMH concentrations beyond the age of
12 years, is in contrast to the recent analysis by Hagen et al.w h i c h
suggested in a cross-sectional study that AMH did not change from
age 8 to age 25 or indeed relative to pubertal stage [29]. Censoring
our own data between these two ages would also suggest that AMH
does not vary markedly, however, this would lose the power of the
broader picture afforded by the entire age range analysis performed
here. The lack of an increase beyond age 12 as suggested by Hagen et
al., is in marked contrast to current and previous studies, which have
all suggested a peak in early adulthood. A recent analysis of 9,601
infertility patients [25] and a smaller study of 82 healthy subjects both
report that AMH concentrations decrease after age 20 [19]. Although
Figure 1. Serum AMH data. The red line is the model that best fits the 3,260 datapoints shown as triangles. The coefficient of determination, r2,i s
0.34, indicating that 34% of variation in serum AMH concentrations is due to age alone. Peak serum AMH is at 24.5 years.
doi:10.1371/journal.pone.0022024.g001
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were substantially smaller incorporating 144 and 58 subjects and the
minimum age was 14 years and 25 years respectively. This smaller
sample size and lack of data from younger (especially neonatal)
subjects may have skewed the reported peaks towards a higher age.
We recognize that although our study has a number of
limitations – including the accuracy of the health status of subjects
in the studies used and the dependence on accurate graphical
presentation of published results – it also has considerable
strengths. The dataset was derived from over 3,500 subjects with
ages ranging from minus 0.3 years to 68 years, the model was then
validated using standard mathematical techniques, with very good
generalisation to unseen data for each of the 10 cross-validation
steps. We did not make any presumptions regarding the optimal
fitting model, yet the optimal model exhibited a non-linear decline
in AMH in adult life consistent with previous cross-sectional and
longitudinal studies [25,34,36,37], and the minipuberty seen in
neonatal girls [29,31,32]. This validated model can therefore be
used to accurately interpret concentrations of serum AMH in
females across the lifespan. The model is based entirely on cross-
sectional data (the small amount of longitudinal data was treated
as if cross-sectional). Further longitudinal validation in similarly
large populations will provide additional confirmation.
It should be noted that our methodological choices have no
effect on the qualitative nature of our results. If we convert to DSL
values instead of IBC, do not add one to the log-adjusted values for
ease of exposition, do not censor at age 54.3, allow models with
more parameters (or restrict to models with slightly fewer
parameters), use k|2 or bootstrap cross-validation, we still obtain
a validated model with similar peaks, r2 and level of generalisation
to unseen data. The current introduction of the GenII AMH assay
(Beckman Coulter) uses the same standards as the IBC assay, thus
we anticipate that the normative model presented (Figure 2) will be
valid for values obtained using that system.
This comprehensive statistical analysis of 3,260 healthy infants,
children and women has facilitated the first validated normative
Table 2. Sample sizes at each age for the AMH model.
Age
(yrs) n
Age
(yrs) n
Age
(yrs) n
Age
(yrs) n
Age
(yrs) n
Age
(yrs) n
ƒ0 144
0 277 10 61 20 21 30 77 40 79 50 25
1 4 31 16 9 2 13 7 3 17 7 4 17 2 5 11 8
2 1 21 26 5 2 22 7 3 21 0 1 4 28 0 5 21 9
3 1 21 36 1 2 33 5 3 37 4 4 36 6 w53 12
4 1 41 48 2 2 43 2 3 49 7 4 45 8
5 1 41 56 1 2 55 0 3 58 4 4 55 9
6 5 11 63 7 2 63 6 3 61 1 6 4 63 6
7 6 01 76 4 2 75 5 3 79 8 4 73 7
8 6 01 84 0 2 86 7 3 81 0 0 4 83 7
9 5 81 94 0 2 94 5 3 98 6 4 92 3
The 3,260 AMH datapoints described in Table 1, split into ages. n denotes the
size of the subset of the data associated with an age in years.
doi:10.1371/journal.pone.0022024.t002
Table 3. 10-fold cross-validation models.
k0 k1 k2 k3 k4 k5 k6 k7 k8 k9 All data
c0 2.70e-01 2.67e-01 2.67e-01 2.67e-01 2.72e-01 2.69e-01 2.67e-01 2.71e-01 2.70e-01 2.68e-01 2.69e-01
c1 2.78e-01 2.91e-01 2.91e-01 2.75e-01 2.84e-01 2.83e-01 2.62e-01 2.50e-01 2.79e-01 2.69e-01 2.77e-01
c2 -1.92e-01 -1.90e-01 -1.90e-01 -1.91e-01 -1.98e-01 -1.78e-01 -1.87e-01 -1.91e-01 -1.86e-01 -1.74e-01 -1.88e-01
c3 -3.21e-02 -4.82e-02 -4.82e-02 -3.27e-02 -3.59e-02 -3.42e-02 -1.54e-02 -2.93e-04 -2.95e-02 -1.66e-02 -2.99e-02
c4 7.17e-02 8.45e-02 8.45e-02 7.22e-02 7.92e-02 6.39e-02 5.99e-02 4.72e-02 6.64e-02 5.14e-02 6.85e-02
c5 -3.13e-02 -3.62e-02 -3.62e-02 -3.14e-02 -3.52e-02 -2.64e-02 -2.78e-02 -2.23e-02 -2.86e-02 -2.27e-02 -3.00e-02
c6 7.56e-03 8.71e-03 8.71e-03 7.57e-03 8.66e-03 6.14e-03 6.98e-03 5.53e-03 6.85e-03 5.55e-03 7.25e-03
c7 -1.21e-03 -1.38e-03 -1.38e-03 -1.20e-03 -1.40e-03 -9.56e-04 -1.15e-03 -8.98e-04 -1.09e-03 -9.02e-04 -1.16e-03
c8 1.38e-04 1.57e-04 1.57e-04 1.37e-04 1.61e-04 1.07e-04 1.35e-04 1.03e-04 1.23e-04 1.05e-04 1.33e-04
c9 -1.17e-05 -1.31e-05 -1.31e-05 -1.15e-05 -1.36e-05 -8.90e-06 -1.16e-05 -8.83e-06 -1.04e-05 -9.08e-06 -1.12e-05
c10 7.50e-07 8.35e-07 8.35e-07 7.33e-07 8.75e-07 5.66e-07 7.61e-07 5.72e-07 6.64e-07 5.97e-07 7.20e-07
c11 -3.71e-08 -4.08e-08 -4.08e-08 -3.60e-08 -4.31e-08 -2.78e-08 -3.83e-08 -2.85e-08 -3.28e-08 -3.02e-08 -3.56e-08
c12 1.43e-09 1.55e-09 1.55e-09 1.38e-09 1.65e-09 1.06e-09 1.49e-09 1.10e-09 1.26e-09 1.19e-09 1.37e-09
c13 -4.27e-11 -4.57e-11 -4.57e-11 -4.09e-11 -4.89e-11 -3.16e-11 -4.50e-11 -3.30e-11 -3.78e-11 -3.63e-11 -4.08e-11
c14 9.89e-13 1.05e-12 1.05e-12 9.41e-13 1.12e-12 7.31e-13 1.05e-12 7.68e-13 8.76e-13 8.56e-13 9.44e-13
c15 -1.76e-14 -1.83e-14 -1.83e-14 -1.66e-14 -1.98e-14 -1.29e-14 -1.88e-14 -1.37e-14 -1.56e-14 -1.55e-14 -1.67e-14
c16 2.34e-16 2.41e-16 2.41e-16 2.21e-16 2.61e-16 1.72e-16 2.52e-16 1.83e-16 2.09e-16 2.10e-16 2.23e-16
c17 -2.27e-18 -2.31e-18 -2.31e-18 -2.13e-18 -2.51e-18 -1.67e-18 -2.46e-18 -1.78e-18 -2.03e-18 -2.06e-18 -2.16e-18
c18 1.51e-20 1.52e-20 1.52e-20 1.41e-20 1.65e-20 1.11e-20 1.64e-20 1.19e-20 1.36e-20 1.39e-20 1.43e-20
c19 -6.16e-23 -6.12e-23 -6.12e-23 -5.74e-23 -6.66e-23 -4.54e-23 -6.74e-23 -4.84e-23 -5.55e-23 -5.75e-23 -5.83e-23
c20 1.16e-25 1.14e-25 1.14e-25 1.08e-25 1.24e-25 8.56e-26 1.27e-25 9.14e-26 1.05e-25 1.10e-25 1.10e-25
The columns are the 21 coefficients cj for the degree 20 polynomial returned by TableCurve2D that gave the highest r2 for the dataset under consideration. For fold ki,
the dataset consisted of all points except the ki test data. After validation of the degree 20 polynomial (Table 3), its coefficients were calculated for the entire dataset
(final column). We report this model as our validated model of serum AMH from conception to menopause.
doi:10.1371/journal.pone.0022024.t003
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menopause. The model provides a means for interpretation of how
an individual’s serum AMH concentration compares with
population norms.
Materials and Methods
Data acquisition
Studies involving serum AMH measurements of human females
were identified by performing PubMed and Medline searches and
searching individual journals (including Menopause, Fertility and
Sterility, Human Reproduction and the Journal of Clinical
Endocrinology and Metabolism) using the search terms AMH,
Mu ¨llerian inhibiting substance, ovarian reserve and polycystic
ovarian syndrome. The references of included studies (Table One;
[19,20,29,34–36,38–49]) were checked to identify further relevant
studies to be processed. Data was selected for this analysis only for
subjects who were not known to be infertile, or have an identified
chronic illness. Hence all subjects were either in control groups
from controlled studies or from prospective studies of the healthy
population. Any data from subjects with a chronic disease or
undergoing infertility assessment or investigation were excluded
from the study. In the main, the data was from pre-menopausal
women. In three studies the menopausal status of the women was
not stated [45,47,49]. Data from fetal blood (n~25) and cord
blood (n~53) of infants [38] were included. Longitudinal data –
from [19,29,40,48] – were recorded as cross-sectional values. The
data were extracted from graphs using Plot Digitizer software [50]
to convert datapoints on the graphs into numerical data. Repeated
datapoints were isolated by requiring that the acquired dataset
Table 4. 10-fold cross-validation results.
k0 k1 k2 k3 k4 k5 k6 k7 k8 k9 Mean
MSE train 0.069 0.068 0.067 0.069 0.069 0.069 0.069 0.069 0.069 0.068 0.069
MSE test 0.064 0.070 0.080 0.065 0.068 0.069 0.067 0.068 0.064 0.078 0.069
r2 0.338 0.338 0.341 0.352 0.343 0.339 0.341 0.340 0.337 0.345 0.341
Age at peak AMH 25.1 21.7 21.5 22.0 25.5 24.5 24.6 24.5 24.1 25.0 23.8
The mean squared error (MSE) for the model with highest r2 is given for both the training set (90% of the dataset) and the test set (the remaining 10%) for each of the
ten folds. Since – both for individual folds and on average – the errors are similar, we consider the model to be validated. The r2 and peak ages are for the highest
ranked model returned by TableCurve2D for each fold.
doi:10.1371/journal.pone.0022024.t004
Figure 2. The normal range for serum AMH in girls and women. The red line is the log-unadjusted validated AMH model using IBC assay
values. The blue and green lines are the 68% and 95% prediction limits for the model (plus and minus one and two standard deviations respectively).
doi:10.1371/journal.pone.0022024.g002
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(Table One).
We combined the resulting dataset with two sets of raw Scottish
data. The first consisted of individual serum AMH measurements
(n=441, median age 36.1 years, max. age 47.8, min age 21.9)
from a cohort of women whose partners were known to have
severe male factor infertility requiring ICSI, and where no other
female cause of infertility had been identified [25]. Individual
patient serum AMH measurements were undertaken between July
2006 and October 2009 in the biochemical laboratories of the
University of Glasgow, the Glasgow Centre for Reproductive
Medicine and the Glasgow Royal Infirmary. All three facilities
were providing centralised AMH testing for infertility clinics
within the United Kingdom. Ethical approval for studies involving
these data was obtained from NHS Scotland. Subjects were
informed that data may be analysed anonymously. Individual
ethical approval has not been taken for studies involving this data,
as it is routine anonymous clinical data which is covered by the
general UK National Health Service ethics for analysis of routine
biochemical data, provided it is anonymous, The second dataset
was supplied by Ahmed et al. [30] and consists of 128
measurements taken from subjects aged 0.5–16.5 years.
Serum AMH values were standardised to give AMH measure-
ments in ng/ml using the conversion formula 1 pmol/
l=7.143 ng/ml.
The resulting data were considered separately depending on the
assay used to obtain serum AMH values. The first dataset
(n=1,990, median age 15.8 years, max. age 68.0, min age 20.3)
came from those studies in which the serum concentrations of
AMH were determined using enzyme-linked immunoassay kits
IBC (Immunotech Beckman Coulter Company, France). The
second dataset (n=1,309, median age 35.4 years, max. age 54.7,
min age 0.2) came from studies in which the enzyme-immuno-
metric assay Active MIS/AMH ELISA kits DSL (Diagnostic
Systems Laboratories Inc., TX, USA) were used. We converted
the DSL data into IBC values using the conversion formula
2:02  DSL~IBC
which has a reported r2 of 0.85 [51], and censored 39 datapoints
over 54.3 years (mean age at menopause plus one standard
deviation [52].) The resulting dataset consists of 3,260 serum
AMH concentrations at known ages, and approximates circulating
AMH concentrations in the healthy population from conception to
menopause.
Data analysis
Stratified 10-fold cross-validation was performed using standard
techniques [53]. The dataset was split into 10 distinct subsets,
k0,...,k9, of nearly equal size, each with similar mean, median,
minimum and maximum. For fold i, ki was retained as test data,
with the remaining 90% of the data used for training purposes. For
each training set we added zero AMH values at conception, in
order to force models through the only known AMH concentra-
tion at any age. Since variability increases with AMH concentra-
tion, we log-adjusted the data (after adding one to each value so
that zero AMH on a chart represents zero serum AMH). All data
were analysed as cross-sectional values (i.e. longitudinal patterns
were not considered). We then fitted 215 mathematical models to
the i-th test data using TableCurve-2D (Systat Software Inc., San
Jose, California, USA), and ranked the results by coefficient of
determination, r2. Each model defines a generic type of curve and
has parameters which, when instantiated gives a specific curve of
that type. For each model we calculated values for the parameters
that maximise the r2 coefficient. The Levenberg-Marquardt non-
linear curve-fitting algorithm was used throughout, with conver-
gence to 5 significant figures after a maximum of 1,000 iterations.
The highest ranked model was chosen as the best model for the
test data, and the mean square error and r2 were calculated after
removing the artificial zero values at conception.
For validation purposes, the mean square error of the ki data for
the i-th model was calculated and compared to the mean square
error of training data for the same model. In other words, the
cross-validation estimate of the prediction error of the model was
compared to the training error of the model. Training error is
expected to be underestimated (due to overfitting of the chosen
data) and the cross-validation estimate of the prediction error is
expected to be overestimated (due to underfitting of unseen data).
We consider a model to be validated if the differences between
these errors is small.
For each fold the highest ranked model was a degree 20
polynomial of the form
log10(AMHz1)~c0zc1agezc2age2z...zc20age20
Hence, after validation (Tables 3 and 4), the 21 parameters for this
model were derived for the entire dataset (n=3,260), again using
TableCurve2D. The resulting model is reported as our validated
model (Figure 2).
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